The questionnaire was sent to 69 eligible women. Among 52 responders, 49 provided data suitable for analysis. In general, participants were young (median 30 years old, range 19-68), white (86%), married (76%), and educated (86% with college degrees). Median duration of vulvodynia and dyspareunia was 2 and 3 years, respectively. Seventy-eight percent had previously failed at least one other treatment. Median treatment duration with VVT was five months (range 1-18) and was introduced after topical therapy, generally consisting of estrogen-containing ointments.
Nearly half of our cohort reported pain during VVT and half found this treatment embarrassing. The majority (70%) of participants, however, found VVT useful in alleviating pain during intercourse. Over 80% reported overall satisfaction and willingness to refer patients with similar complaints. Ninety percent rated VVT as affordable and easy. No complications were noted. VVT is a novel treatment for both vulvodynia and entry dyspareunia which has provided subjective relief when other therapies failed. VVT is safe, inexpensive, and appears acceptable to the majority of patients. Further study is needed to better quantify reponse and invertigate the potential mechanism(s) of action of VVT (e.g. anti-nocioceptive properties of vibration).
This presentation, "Responding to the needs of consumers with complex trauma histories a consumer perspective" focuses on the needs of adult survivors of child abuse, highlighting the frequent